[1]
Montgomery DM, Brower RS. Cervical spondylotic myelopathy. Clinical syndrome and natural history. Orthop Clin North Am 1992; 23: 487-93.
[2]
Young WF. Cervical spondylotic myelopathy, a common cause of spinal cord dysfunction in older persons. Am Fam Physician 2000; 62: 1064-1070, 1073.
[3]
Shedid D, Benzel EC. Cervical spondylosis anatomy, pathophysiology and biomechanics. Neurosurgery 2007; 60: S7-S13.
[4]
Baptiste DC, Fehlings MG. Pathophysiology of cervical myelopathy. Spine J 2006; 6: 190S-7S.
[5]
Baron EM, Young WF. Cervical spondylotic myelopathy. A brief review of its pathophysiology, clinical course, and diagnosis. Neurosurgery 2007; 60: S35-41.
[6]
Fernandez de Rota JJ, Meschian S, Fernandez de Rota A, Urbano V, Baron M. Cervical spondylotic myelopathy due to chronic compression, the role of signal intensity changes in magnetic resonance images. J Neurosurg Spine 2007; 6: 17-22.
[7]
Kim P, Haisa T, Kawamoto T, Kirino T, Wakai S. Delayed myelopathy induced by chronic compression in the rat spinal cord. Ann Neurol 2004; 55: 503-11.
[8]
Karadimas SK, Erwin WM, Ely CG, Dettori JR, Fehlings MG. Pathophysiology and natural history of cervical spondylotic myelopathy. Spine 2013; 38: S21-36.
[9]
Lee J, Satkunendrarajah K, Fehlings MG. Development and characterization of a novel rat model of cervical spondylotic myelopathy, the impact of chronic cord compression on clinical, neuroanatomical and neurophysiological outcomes. J Neurotrauma 2012; 29: 1012-27.
[10]
Moon ES, Karadimas SK, Yu WR, Austin JW, Fehlings MG. Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. Neurobiol Dis 2014; 62: 394-406.
[11]
Yamamoto S, Kurokawa R, Kim P. Cilostazol, a selective Type III phosphodiesterase inhibitor: Prevention of cervical myelopathy in a rat chronic compression model. J Neurosurg Spine 2014; 20: 93-101.
[12]
Dhillon RS, Parker J, Syed YA, et al. Axonal plasticity underpins the functional recovery following surgical decompression in a rat model of cervical spondylotic myelopathy. Acta Neuropathol Commun 2016; 4: 89.
[13]
Karadimas SK, Moon ES, Yu WR, et al. A novel experimental model of Cervical Spondylotic Myelopathy (CSM) to facilitate translational research. Neurobiol Dis 2013; 54: 43-58.
[14]
Fehlings MG, Wilson JR, Kopjar B, et al. Efficacy and safety of surgical decompression in patients with cervical spondylotic myelopathy. Results of the AOSpine North America prospective multi-center study. J Bone Joint Surg Am 2013; 95: 1651-8.
[15]
Liao B, Newmark H, Zhou R. Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. Exp Neurol 2002; 173: 224-34.
[16]
Huang F, Li YN, Yin F, et al. Ginsenoside Rb1 inhibits neuronal apoptosis and damage, enhances spinal aquaporin 4 expression and improves neurological deficits in rats with spinal cord ischemiareperfusion injury. Mol Med Rep 2015; 11: 3565-72.
[17]
Wang P, Lin C, Wu S, et al. Inhibition of autophagy is involved in the protective effects of ginsenoside Rb1 on spinal cord injury. Cell Mol Neurobiol 2018; 38: 679-90.
[18]
Xu L, Huang SP. Effect of the ginsenoside Rb1 on the spontaneous contraction of intestinal smooth muscle in mice. World J Gastroenterol 2012; 18: 5462-9.
[19]
Yan S, Li Z, Li H, Arancio O, Zhang W. Notoginsenoside R1 increases neuronal excitability and ameliorates synaptic and memory dysfunction following amyloid elevation. Sci Rep 2014; 4: 6352.
[20]
Hu Z, Yang J, Cheng C, et al. Combinatorial metabolism notably affects human systemic exposure to ginsenosides from orally administered extract of Panax notoginseng roots (Sanqi). Drug Metab Dispos 2013; 41: 1457-69.
[21]
Guo S, Chen Y, Pang C, et al. Ginsenoside Rb1, a novel activator of the TMEM16A chloride channel, augments the contraction of guinea pig ileum. Pflugers Arch 2017; 469: 681-92.
[22]
Neumann M, Wang Y, Kim S, et al. Assessing gait impairment following experimental traumatic brain injury in mice. J Neurosci Methods 2009; 176: 34-44.
[23]
Dias DO, Kim H, Holl D, et al. Reducing pericyte-derived scarring promotes recovery after spinal cord injury Cell 2018; 173: 153-165 e22.
[24]
Li LH, Wang ZC, Yu J, Zhang YQ. Ovariectomy results in variable changes in nociception, mood and depression in adult female rats. PLoS One 2014; 9e94312
[25]
Chen G, Kim YH, Li H, et al. PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat Neurosci 2017; 20: 917-26.
[26]
Yang L, Su J, Zhang X, Jiang C. Hypercapnia modulates synaptic interaction of cultured brainstem neurons. Respir Physiol Neurobiol 2008; 160: 147-59.
[27]
Wang H, Yu LC, Li YC. Protein tyrosine kinase regulates alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking induced by acute hypoxia in cultured brainstem neurons. Genet Mol Res 2016; 15(3)
[28]
Huang Y, Liu X, Wang G, Wang Y. SK channels participate in the formation of after burst hyperpolarization and partly inhibit the burst strength of epileptic ictal discharges. Mol Med Rep 2018; 17: 1762-74.
[29]
Huang Y, Zhang Y, Kong S, et al. GIRK1-mediated inwardly rectifying potassium current suppresses the epileptiform burst activities and the potential antiepileptic effect of ML297. Biomed Pharmacother 2018; 101: 362-70.
[30]
Guo Q, Li P, Wang Z, et al. Brain distribution pharmacokinetics and integrated pharmacokinetics of Panax Notoginsenoside R1, Ginsenosides Rg1, Rb1, Re and Rd in rats after intranasal administration of Panax notoginseng saponins assessed by UPLC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 969: 264-71.
[31]
Zhang Y, Lu N, Zhao ZQ, Zhang YQ. Involvement of estrogen in rapid pain modulation in the rat spinal cord. Neurochem Res 2012; 37: 2697-705.
[32]
Lopez MV, Cuadrado MP, Ruiz-Poveda OM, Del Fresno AM, Accame ME. Neuroprotective effect of individual ginsenosides on astrocytes primary culture. Biochim Biophys Acta 2007; 1770: 1308-16.
[33]
Liu J, He J, Huang L, Dou L, Wu S, Yuan Q. Neuroprotective effects of ginsenoside Rb1 on hippocampal neuronal injury and neurite outgrowth. Neural Regen Res 2014; 9: 943-50.
[34]
Ahmed T, Raza SH, Maryam A, et al. Ginsenoside Rb1 as a neuroprotective agent. A review. Brain Res Bull 2016; 125: 30-43.
[35]
Huang Y, Wang Y, Yan R, et al. The role of traditional Chinese herbal medicines and bioactive ingredients on ion channels: A brief review and prospect. CNS Neurol Disord Drug Targets 2018.
[36]
Liu WJ, Tang HT, Jia YT, et al. Notoginsenoside R1 attenuates renal ischemia-reperfusion injury in rats. Shock 2010; 34: 314-20.
[37]
Li C, Li Q, Liu YY, et al. Protective effects of notoginsenoside R1 on intestinal ischemia-reperfusion injury in rats. Am J Physiol Gastrointest Liver Physiol 2014; 306: G111-22.
[38]
Zhong L, Zhou XL, Liu YS, et al. Estrogen receptor alpha mediates the effects of notoginsenoside R1 on endotoxin-induced inflammatory and apoptotic responses in H9c2 cardiomyocytes. Mol Med Rep 2015; 12: 119-26.
[39]
Wang Y, Tu L, Li Y, Chen D, Wang S. Notoginsenoside R1 protects against neonatal cerebral hypoxic-ischemic injury through estrogen receptor-dependent activation of endoplasmic reticulum stress pathways. J Pharmacol Exp Ther 2016; 357: 591-605.
[40]
Lujan R, Marron Fernandez de Velasco E, Aguado C, Wickman K. New insights into the therapeutic potential of Girk channels. Trends Neurosci 2014; 37: 20-9.
[41]
Mao J, Wang X, Chen F, et al. Molecular basis for the inhibition of G protein-coupled inward rectifier K(+) channels by protein kinase C. Proc Natl Acad Sci USA 2004; 101: 1087-92.
[42]
Adney SK, Ha J, Meng XY, Kawano T, Logothetis DE. A critical gating switch at a modulatory site in neuronal Kir3 channels. J Neurosci 2015; 35: 14397-405.
[43]
Samarghandian S, Farkhondeh T, Samini F. A review on possible therapeutic effect of Nigella sativa and thymoquinone in neurodegenerative diseases. CNS Neurol Disord Drug Targets 2018; 17: 412-20.
[44]
Wake R, Miyaoka T, Furuya M, Hashioka S, Horiguchi J. Effects of Yokukansan, a Japanese Kampo medicine for symptoms associated autism spectrum disorder. CNS Neurol Disord Drug Targets 2016; 15: 551-63.
[45]
Lu JM, Yao Q, Chen C. Ginseng compounds: An update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009; 7: 293-302.
[46]
Zhao J, Lu S, Yu H, Duan S, Zhao J. Baicalin and ginsenoside Rb1 promote the proliferation and differentiation of neural stem cells in Alzheimer’s disease model rats. Brain Res 2018; 1678: 187-94.
[47]
Zhang YL, Liu Y, Kang XP, et al. Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson’s disease. Neuropharmacology 2018; 131: 223-37.
[48]
Olby NJ, Sharp NJ, Munana KR, Papich MG. Chronic and acute compressive spinal cord lesions in dogs due to intervertebral disc herniation are associated with elevation in lumbar cerebrospinal fluid glutamate concentration. J Neurotrauma 1999; 16: 1215-24.
[49]
Fehlings MG, Wilson JR, Karadimas SK, Arnold PM, Kopjar B. Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: Design and rationale for the CSM-Protect trial. Spine (Phila Pa 1976) 2013; 38: S68-75.
[50]
Fehlings MG, Ibrahim A, Tetreault L, et al. A global perspective on the outcomes of surgical decompression in patients with cervical spondylotic myelopathy, results from the prospective multicenter AOSpine international study on 479 patients. Spine (Phila Pa 1976) 2015; 40: 1322-8.
[51]
Gao XQ, Yang CX, Chen GJ, et al. Ginsenoside Rb1 regulates the expressions of brain-derived neurotrophic factor and caspase-3 and induces neurogenesis in rats with experimental cerebral ischemia. J Ethnopharmacol 2010; 132: 393-9.
[52]
Hama A, Natsume T, Ogawa SY, et al. Pain-related behavior and brain activation in a cynomolgus macaque model of postoperative pain. CNS Neurol Disord Drug Targets 2018; 17: 348-60.
[53]
Islam N, Abbas M, Rahman S. Neuropathic pain and lung delivery of nanoparticulate drugs, an emerging novel therapeutic strategy. CNS Neurol Disord Drug Targets 2017; 16: 303-10.
[54]
Raghavendra V, Tanga FY, DeLeo JA. Complete freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci 2004; 20: 467-73.
[55]
Obata H, Eisenach JC, Hussain H, Bynum T, Vincler M. Spinal glial activation contributes to postoperative mechanical hypersensitivity in the rat. J Pain 2006; 7: 816-22.
[56]
Hald A, Nedergaard S, Hansen RR, Ding M, Heegaard AM. Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain. Eur J Pain 2009; 13: 138-45.
[57]
De Filippis L, Zalfa C, Ferrari D. Neural stem cells and human induced pluripotent stem cells to model rare CNS diseases. CNS Neurol Disord Drug Targets 2017; 16: 915-26.
46
2